Roivant Sciences Cash Flow Statement
NASDAQ: ROIVHealth CareBiotechnology: Pharmaceutical PreparationsUSD
35.44+1.23 (+3.60%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Roivant Sciences free cash flow
In fiscal 2025, Roivant Sciences generated -$750.3 million of operating cash flow and spent $8.2 million on capital expenditures. That left free cash flow of -$758.6 million, a free-cash-flow margin of -9183.5% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Roivant Sciences cash flow statement (annual)
| Fiscal year (USD) | FY 20252026-03-31 | FY 20242025-03-31 | FY 20232024-03-31 | FY 20232023-03-31 | FY 20222022-03-31 | FY 20202021-03-31 |
|---|---|---|---|---|---|---|
| Net Income | -397.91M | -356.73M | 4.23B | -1.12B | -924.12M | -900.23M |
| Net Income growth (YoY) | — | -108.43% | — | — | — | — |
| Depreciation & Amortization | 3.35M | 14.07M | 22.04M | 18.86M | 5.93M | — |
| Stock-Based Compensation | 346.17M | 289.03M | 199.63M | 217.78M | 564.96M | 84.96M |
| Change in Working Capital | 2.41M | -17.39M | 20.30M | 6.51M | 83.97M | 15.27M |
| Operating Cash Flow | -750.35M | -839.45M | -765.27M | -843.39M | -677.73M | -552.14M |
| Capital Expenditures | -8.21M | -4.60M | -1.38M | -12.69M | -17.44M | -5.81M |
| Investing Cash Flow | -682.33M | -1.77B | 5.20B | -44.27M | 303.30M | -31.70M |
| Share Repurchases | — | -1.29B | 0 | 0 | — | — |
| Financing Cash Flow | 134.24M | -1.22B | 419.36M | 499.46M | 306.79M | 456.26M |
| Net Change in Cash | -1.29B | -3.82B | 4.86B | -381.92M | -67.64M | -127.58M |
| Free Cash Flow | -758.56M | -844.05M | -766.65M | -856.08M | -695.16M | -557.94M |
This table shows 6 annual periods of Roivant Sciences's cash flow statement, from FY 2025 back to FY 2020, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ROIV's reporting calendar. What is a cash flow statement?